Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
10-Q
Rhea-AI Filing Summary
Bio Essence Corp. reported a sharp turnaround for the six months ended June 30, 2026, posting net income of $475,450 versus a loss a year earlier, on a more than tripling of OEM service revenues to $1,295,248. Gross profit rose to $789,614, and operating income reached $495,085.
Total assets increased to $4,002,945, driven largely by the acquisition of the MediFlow AI software, recorded as $3,396,438 of intangible assets after amortization. The company issued 15,800,000 new common shares during the period, including 8,800,000 shares for $440,000 of cash and 7,000,000 shares valued at $3,500,000 for the software.
Despite profitability, Bio Essence had cash of only $675, a working capital deficit of $998,524, and an accumulated deficit of $9,077,623. Management states that these factors, along with dependence on additional financing, raise substantial doubt about the ability to continue as a going concern. The company also carries about $1.5 million in operating lease liabilities tied to a disputed facility lease and acknowledges that disclosure controls and internal control over financial reporting are not effective.
Positive
- Net income of $475,450 for the six months ended June 30, 2026, compared with a prior-year loss, indicates substantially improved profitability.
- Revenues grew to $1,295,248, more than quadrupling year over year, driven by higher OEM service volumes and new major customers.
- Gross profit increased to $789,614, with positive operating income of $495,085, showing the OEM-focused model is currently generating operating profits.
- Working capital deficit narrowed from $2,016,834 at December 31, 2025 to $998,524 at June 30, 2026, reflecting improved current-position metrics.
- The company closed a non-cash $3,500,000 acquisition of MediFlow AI software, potentially expanding capabilities while preserving cash.
- Equity improved from a deficit of $(2,072,893) to positive stockholders’ equity of $2,342,557, materially strengthening the balance sheet.
Negative
- Management discloses that accumulated deficit of $9,077,623 and dependence on additional financing raise substantial doubt about the ability to continue as a going concern.
- Liquidity is very tight, with cash of only $675 and a working capital deficit of $998,524 at June 30, 2026, while management estimates it needs $1.2 million to fund 12 months of operations.
- The company has recorded approximately $1.5 million in operating lease liabilities related to disputed Irvine facility obligations and faces related litigation seeking similar damages.
- Disclosure controls and procedures and internal control over financial reporting are reported as not effective, increasing the risk of errors or misstatements in financial reporting.
- A $470,000 loan to a CEO-controlled entity represents a sizable related party exposure for a business already experiencing liquidity constraints.
- Revenues and manufacturing services are highly concentrated, with two customers accounting for 46.2% and 19.3% of six-month sales and two vendors providing nearly all manufacturing services.
